Phaseline

Targets › RAC1

RAC1 (Ras-related C3 botulinum toxin substrate 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Plasma membrane-associated small GTPase which cycles between active GTP-bound and inactive GDP-bound states. In its active state, binds to a variety of effector proteins to regulate cellular responses such as secretory processes, phagocytosis of apoptotic cells, epithelial cell polarization, neurons adhesion, migration and differentiation, and growth-factor induced formation of membrane ruffles. (UniProt, P63000)

Open in Phaseline: the race on RAC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
MBQ PharmaMBQ-167
Rho GTPase inhibitor (Rac and Cdc42 inhibitor)
RAC1, CDC42Phase 1Breast CancerDec 2026

Conditions

Breast Cancer (1)

Modalities

small molecule (1)

Companies

MBQ Pharma (1)

Related targets

CDC42 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.